MedTrace Logo

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-02-22

No results posted yet for this study

Summary

To determine if the use of impedance cardiography can identify appropriate medications for use in treating morbidly obese patients to decrease the risk of preeclampsia.

Conditions

Interventions

DRUG

Labetalol Hydrochloride 200 mg

Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography

DRUG

NIFEdipine 60 mg

Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography

DRUG

Atenolol 25 mg

Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater

Sponsors & Collaborators

  • University of Tennessee Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Craig V. Towers, MD · University of Tennessee Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2019-12-31
Completion
2020-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105661 on ClinicalTrials.gov